BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 03/10/2016
Entire Document
 
5

 
BioLineRx Ltd.
 
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

   
Year ended December 31,
 
   
2013
   
2014
   
2015
 
   
in USD thousands
 
                   
RESEARCH AND DEVELOPMENT EXPENSES, NET
    (12,208 )     (11,866 )     (11,489 )
SALES AND MARKETING EXPENSES
    (1,136 )     (1,589 )     (1,003 )
GENERAL AND ADMINISTRATIVE EXPENSES
    (3,664 )     (3,800 )     (3,704 )
OPERATING LOSS
    (17,008 )     (17,255 )     (16,196 )
NON-OPERATING INCOME, NET
    1,161       3,061       1,445  
FINANCIAL INCOME
    720       3,566       457  
FINANCIAL EXPENSES
    (1,897 )     (448 )     (106 )
NET LOSS
    (17,024 )     (11,076 )     (14,400 )
OTHER COMPREHENSIVE INCOME (LOSS):
                       
CURRENCY TRANSLATION DIFFERENCES
    1,097       (2,834 )     -  
COMPREHENSIVE LOSS
    (15,927 )     (13,910 )     (14,400 )
 
   
in USD
 
LOSS PER ORDINARY SHARE – BASIC AND DILUTED
    (0.76 )     (0.34 )     (0.28 )
                         
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE
    22,488,516       32,433,883       51,406,434